The LiBBY trial — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol — eased agitation in advanced dementia but showed more serious illness on treatment. For adults with memory concerns, the findings give no support for using cannabis oils to prevent or treat early symptoms. The Phase 2 study enrolled 120 hospice-eligible patients with dementia and agitation.
The Alzheimer's Association describes 10 U.S. sites with home visits in its AAIC topline release. Treatment lasted 12 weeks.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the oil contained and how agitation changed
- What drove the safety concern?
- Why early memory concerns are different
- What practical steps help now?
What the oil contained and how agitation changed
Patients received a purified oral oil called T2:C100. Each dose held 2 mg THC plus 100 mg CBD. Week 1 used a half dose, then full dosing ran twice daily from Week 2 through Week 12. Neuroscience News describes this schedule. Agitation dropped more on active oil than on placebo.
Neuroscience News reports a 6.27-point larger drop by Week 2 and an 8.23-point larger drop through Week 12 in its trial summary. The tool was the Cohen-Mansfield Agitation Inventory. It scores pacing, restlessness, shouting, and aggression. NeurologyLive reports clinician-rated improvement of 83.9% on treatment versus 30.5% on placebo at Week 2. The gap held at Week 12, at 87.2% versus 23.6%. The reported P value was less than .0001.
What drove the safety concern?
ScienMag reports overall adverse events were close, at 46.7% on oil and 42.4% on placebo. Serious events were higher on oil, at 23.3% versus 11.9%. Serious here means hospital stay, life threat, or death.
Investigators judged none of the serious events drug-related. NeurologyLive highlights the core worry in its safety report: serious infections at 11.7% versus 1.7% and deaths at 13.1% versus 5.1%. Patients were frail and near end of life. That frailty makes any added risk weigh heavily.
Why early memory concerns are different
NeurologyLive notes this was a small 12-week Phase 2 topline result. Patients averaged 80 years old and were hospice-eligible with advanced dementia. The trial did not enroll adults with early or mild memory concerns. Late-stage agitation has different causes than early forgetfulness. Drugs that calm severe distress may not help memory.
Prevention and early treatment need separate trials. Think of it like wound care versus skin care. One treats fragile skin at high risk. The other aims to keep healthy skin healthy. Results from the first setting do not transfer to the second.
What practical steps help now?
Do not swap in dispensary or over-the-counter cannabis for this oil. The trial used a supervised pharmaceutical-grade formula. NeurologyLive's report on the FDA warning notes only Dronabinol, Epidiolex, Marinol and Syndros are approved cannabis-derived medicines in its FDA warning summary. The agency warns against Alzheimer's claims for other CBD products.
Bring clear notes to the clinic visit. They help the team spot medical causes and safer options. Keep cannabis products out of reach until the clinician reviews risks. Bring that list to the next visit and ask which non-drug steps to try first.
- List all drugs, sleep aids, alcohol, and cannabis products with doses
- Note when agitation peaks, what triggers it, and what calms it
- Ask about pain, infection, sleep, hearing, vision, and daily routine checks
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: What the Findings Mean for Adults With Memory Concerns
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: What the Findings Mean for Adults With Memory Concerns
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What the Findings Mean for Adults With Memory Concerns
